Alere confirmed analysts’ suspicions that Abbott Laboratories is reticent about its planned $5.8bn takeover of the embattled diagnostics company, but the deal appears to be back on track, for now.
Abbott agreed to buy Alere in February for $56 per share, a 50% premium over its last share price,...





